Pacific Biosciences of California, Inc. PACB
Regular-session close
After hours · Nov 13, 6:42 PM ET
- YTD
- +4.81%
- 1 year
- +20.25%
Discussion (182)
Sign in to join the discussion
Brennan you have not proved a point. $BNGO is not planning on developing a sequencer in the near future. They have the paten so they can decide if they want to. If they do decide to, you’re talking years down the road. You have not proved that $BNGO is a competitor of $PACB. They are not in the same market and $BNGO said it is not on their roadmap in the same article you cherry pick information from.
Brennan you have not proved a point. $BNGO is not planning on developing a sequencer in the near future. They have the paten so they can decide if they want to. If they do decide to, you’re talking years down the road. You have not proved that $BNGO is a competitor of $PACB. They are not in the same marketplace and have said it is not on their roadmap in the same article you cherry pick information from.
Brennan you have not proved a point. $BNGO is not planning on developing a sequencer. They have the patton so they can decide if they want to. If they do decide to, you’re talking years down the road. You have not proved that $BNGO is a competitor of $PACB. They are not in the same marketplace and have said it is not on their roadmap in the same article you cherry pick information from.
$BNGO has filed a patent to develop a sequencer, but has announced it is not on their roadmap for the future at this time. This means it is not the addressable market they are focusing on.
Improving the ability for a long read sequencing platforms to detect large structural variants is probably going to come from neural network assisted variant calling such as Google’s DeepVariant instead of the extension and read length. DeepVarient is a deep learning system already incorporated into PacBio’s machines and is constantly improving.
Meanwhile $PACB has partnered with Invitae to develop a ultra-high-throughput clinical whole genome sequencing platform using $PACB’s HiFi reads for main stream healthcare. Invitae is the most progressive lab in the country who see’s artificial intelligence as the only way to make the massive amounts of genetic data being generated affordable, scalable and actionable.
If I was going to bet on a sequencer, I wouldn’t put my money in $BNGO. They have no plans to do anything in that market for the foreseeable future. That is what a development roadmap is. I would bet on $BNGO if I was looking to invest in a gene mapping device to replace legacy cytogenetic systems, which are not great at all.
$BNGO does gene mapping. $PACB does gene sequencing, specifically Next Generation Sequencieng (NGS). A sequence spells out the order of every DNA base in the genome, while a map simply identifies a series of landmarks in the genome. They are complementary and have different uses. If approved by the FDA, the Saphyr system will replace current processes for cytogenetics (karyotyping, FISH analysis, and chromosomal microarray). It will not replace clinical processes that require whole genome sequencing, such as CRISPR-Cas9 gene editing. $BNGO has filed a patent to develop a sequencer, but has announced it is not on their roadmap for the future at this time.
Revenues for NGS are expected to grow at an annual rate of 43%, from $3.5 billion last year to $21 billion in 2024. Genome sequencing is set to explode as the cost comes down. If you think $ILMN is going to stay on top in the sequencing market, go ahead and invest in that and good luck. I don’t think the market shares your sentiment.
It’s not going to take much work for $PACB to dethrone $ILMN once $PACB gets the cost of HiFi reads down to that of $ILMN short reads. By 2025, Ark believes both will cost about the same, being at or around $100-$500 for a full human genome. Pacific Biosciences has also mentioned that it is targeting to achieve a 30-fold improvement in the current throughput within a couple of years.
The only reason Ark sells $PACB is to keep the portfolio weighting in line as it continues to grow. They do the same thing with Tesla. If you notice, it’s very small portions and their thesis has not changed. When they closed out their $ILMN position, they sold large chucks at a time. There is a difference.
What’s with all the gay bears on this board?
BNGO does gene mapping. PACB does gene sequencing, specifically Next Generation Sequencieng (NGS). A sequence spells out the order of every DNA base in the genome, while a map simply identifies a series of landmarks in the genome. They are complementary and have different uses. If approved by the FDA, the Saphyr system will replace current processes for cytogenetics (karyotyping, FISH analysis, and chromosomal microarray). It will not replace processes that require sequencing.
Revenues for NGS are expected to grow at an annual rate of 43%, from $3.5 billion last year to $21 billion in 2024. Genome sequencing is set to explode as the cost comes down. If you think $ILMN is going to stay on top in the sequencing market, go ahead and invest in that and good luck. I don’t think the market shares your sentiment.
It’s not going to take much work for $PACB to dethrone $ILMN once $PACB gets the cost of HiFi reads down to that of $ILMN short reads. By 2025, Ark believes both will cost about the same, being at or around $100-$500 for a full human genome. Pacific Biosciences has also mentioned that it is targeting to achieve a 30-fold improvement in the current throughput within a couple of years.
The only reason Ark sells $PACB is to keep the portfolio weighting in line as it continues to grow. They do the same thing with Tesla. If you notice, it’s very small portions and their thesis has not changed. When they closed out their $ILMN position, they sold large chucks at a time. There is a difference.
It’s not going to take much work for $PACB to dethrone $ILMN once $PACB gets the cost of HiFi reads to the same cost as $ILMN short reads. By 2025, Ark believes both will cost about the same, being at or around $100-$500 for a full human genome. Pacific Biosciences has also mentioned that it is targeting to achieve a 30-fold improvement in the current throughput within a couple of years.
